AqueSys: Allergan Shells Out $300 Million+ for SoCal Eye Device Maker AqueSys

Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering- Acquisition Adds Global Rights to XEN45, a Minimally Invasive Best-In-Class Implantable Shunt for Glaucoma --- XEN45 Approved in Global Markets; Late-Stage Development in the US --- Bolsters Allergan's Development and Commercialization...